REGN P/E ratio: current value, 10-year range and year-by-year history
Cash & Leverage
REGN's p/e ratio is right around its 10-year median of 19.8.
P/E ratio History
REGN P/E ratio by year
Yearly range of REGN’s p/e ratio from 2016 to 2026. Over the full period it ranged from 7.8 to 65.4, averaging 23.2.
| Year | Low | Average | High | Year-end |
|---|---|---|---|---|
| 2026 | 14.6 | 17.8 | 21.1 | 20.5 |
| 2025 | 12.3 | 15.6 | 19.5 | 18.6 |
| 2024 | 17.4 | 26.5 | 31.8 | 18.6 |
| 2023 | 17.8 | 21.2 | 25.1 | 25.1 |
| 2022 | 7.8 | 11.6 | 16.2 | 15.2 |
| 2021 | 8.7 | 12.7 | 17.9 | 8.8 |
| 2020 | 15.8 | 23.5 | 32.4 | 15.8 |
| 2019 | 14.2 | 17.4 | 20.6 | 20.3 |
| 2018 | 17.5 | 27.5 | 38.2 | 17.5 |
| 2017 | 32.6 | 46.2 | 63.4 | 34.1 |
| 2016 | 48.8 | 56.8 | 65.4 | 53.3 |
Get notified when REGN P/E ratio crosses a threshold
Free — one alert setup, notifications by push, Telegram, or Discord.
How much the market pays for each dollar of annual profit. P/E = Stock Price / EPS. The raw number means little — what matters is whether it's high or low relative to the company's own history.
Price / Earnings Per ShareThe chart shows five color-coded historical zones: green (below 10th percentile) means historically very cheap, fading through lime and gray (the normal 25th–75th range) to orange and red (historically expensive). When the line sits in a green or lime zone, the stock is trading at an unusually low P/E relative to its own history.
- Cyclical businesses look cheapest on P/E at peak earnings — the "earnings trap." Use EV/EBITDA or normalised earnings for energy, materials, and financials.
- A falling P/E trend may signal a business in structural decline, not a buying opportunity.
Is REGN P/E ratio High or Low Right Now?
Regeneron Pharmaceuticals, Inc.'s P/E ratio is currently 20.5, which is around average relative to its 10-year historical range. The 10-year median P/E ratio for REGN is approximately 19.8. See all REGN valuation metrics →
Unlock 10y, 15y, 20y, and 30y history with peer comparison and CSV export.